Roche’s SMA treatment Evrysdi demonstrates continued improvements in infants by Lucy Parsons | Apr 16, 2021 | News | 0 Drug continuously improved motor function and survival in babies after 24 months of treatment Read More
Roche scores EU approval for at-home SMA treatment Evrysdi by Lucy Parsons | Mar 31, 2021 | News | 0 Therapy indicated for use in SMA patients aged two months and older Read More
EU regulators to review Evrysdi for SMA by Selina McKee | Aug 18, 2020 | News | 0 The decision triggers a £15m milestone payment from Roche to PTC Therapeutics Read More